213 related articles for article (PubMed ID: 16370935)
1. Rubitecan.
Clark JW
Expert Opin Investig Drugs; 2006 Jan; 15(1):71-9. PubMed ID: 16370935
[TBL] [Abstract][Full Text] [Related]
2. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
3. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Schöffski P; Herr A; Vermorken JB; Van den Brande J; Beijnen JH; Rosing H; Volk J; Ganser A; Adank S; Botma HJ; Wanders J
Eur J Cancer; 2002 Apr; 38(6):807-13. PubMed ID: 11937315
[TBL] [Abstract][Full Text] [Related]
4. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Herben VM; Ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Pharm World Sci; 1998 Aug; 20(4):161-72. PubMed ID: 9762728
[TBL] [Abstract][Full Text] [Related]
6. Camptothecins: a review of their chemotherapeutic potential.
Ulukan H; Swaan PW
Drugs; 2002; 62(14):2039-57. PubMed ID: 12269849
[TBL] [Abstract][Full Text] [Related]
7. Alternative administration of camptothecin analogues.
Verschraegen CF; Jaeckle K; Giovanella B; Knight V; Gilbert BE
Ann N Y Acad Sci; 2000; 922():237-46. PubMed ID: 11193899
[TBL] [Abstract][Full Text] [Related]
8. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
9. [A symphony for the camptothecins].
Lansiaux A; Bailly C
Bull Cancer; 2003 Mar; 90(3):239-45. PubMed ID: 12801826
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
Burris HA; Rivkin S; Reynolds R; Harris J; Wax A; Gerstein H; Mettinger KL; Staddon A
Oncologist; 2005 Mar; 10(3):183-90. PubMed ID: 15793221
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent efficacy of camptothecins in models of human cancer.
Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA
Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512
[No Abstract] [Full Text] [Related]
13. Camptothecin design and delivery approaches for elevating anti-topoisomerase I activities in vivo.
Burke TG; Bom D
Ann N Y Acad Sci; 2000; 922():36-45. PubMed ID: 11193923
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
15. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
16. Alternative administration of camptothecin analogues.
Glaberman U; Rabinowitz I; Verschraegen CF
Expert Opin Drug Deliv; 2005 Mar; 2(2):323-33. PubMed ID: 16296757
[TBL] [Abstract][Full Text] [Related]
17. Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology.
Vassal G; Pondarré C; Boland I; Cappelli C; Santos A; Thomas C; Lucchi E; Imadalou K; Pein F; Morizet J; Gouyette A
Biochimie; 1998 Mar; 80(3):271-80. PubMed ID: 9615866
[TBL] [Abstract][Full Text] [Related]
18. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
19. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
20. The development of camptothecin analogs in childhood cancers.
Bomgaars L; Berg SL; Blaney SM
Oncologist; 2001; 6(6):506-16. PubMed ID: 11743213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
